Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Beovu is indicated in adults for the treatment of neovascular (wet) AMD and visual impairment due to diabetic macular oedema (DMO).1,2

The Summary of Product Characteristics (SmPC) of Beovu can be viewed by clicking here for GB and here for NI. 

beovu_timeline_image

See KESTREL & KITE data

Banner with KESTREL and KITE logos. Text: See 'KESTREL & KITE data'

 

The wording 'One year of redefining fluid control' with an animated gif of a brightly covered painting filling up the inside of the O

It has been over 1 year of Beovu experience in the UK since positive NICE and SMC approvals.3,4

Discover the HAWK and HARRIER clinical trials of Beovu and access a range of educational videos hosted by experts in the field of ophthalmology.

 

 
 

Beovu units sold worldwide…

…over 400,000

More than 400,000 units of Beovu worldwide since launch, as of February 2022*5

 

*The numbers of Beovu units sold since October 2019 until February 2022.5

. Text box with NICE recommendation

Text box with SMC review

 

AMD, age-related macular degeneration; NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium.

References

  1. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Great Britain, April 2022.
  2. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Northern Ireland, March 2022.
  3. National institute for Health and Care Excellence (2021) Brolucizumab for treating wet age-related macular degeneration (NICE guideline 672). Available at: https://www.nice.org.uk/guidance/ta672. [Accessed May 2022].
  4. Scottish Medicines Consortium. Available at: https://www.scottishmedicines.org.uk/medicines-advice/brolucizumab-beovu-full-smc2272/ [Accessed May 2022].
  5. Novartis UK data on file. BRO008, 2022.

 

What is Beovu?

 

Efficacy in DMO

 

Safety profile

 

HAWK and HARRIER clinical trials

 
Rate this content: 
No votes yet
UK | May 2022 | 140363-3
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]